INDIANAPOLIS — Over the next eight years, Eli Lilly and Company and Purdue University will continue their partnership. According to an announcement on Friday morning, Lilly is expected to invest ...

Eli Lilly has unveiled plans to expand its long-standing partnership with Purdue University, with the drugmaker investing up to $250m into the collaboration over the next eight years. The alliance, ...

Pharmaceutical giant Eli Lilly will invest $250 million in an eight-year research partnership with Purdue University. Why it matters: There's a lot of uncertainty around federal research funding ...

Eli Lilly had previously announced an expansion of its partnership with Purdue University, with a planned investment of up to $250m over the next eight years to accelerate innovation across the ...

At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrati Eli Lilly and Company (NYSE: LLY) and Purdue University ... This partnership, which has the ...

In other recent news, Eli Lilly has made significant strides with multiple developments. The company announced an expansion of its partnership with Purdue University, committing up to $250 million ...

Purdue has started experimenting with “360 partnership task forces” with Eli Lilly and Company and SK hynix, with growth toward some of the other 400 companies we partner with. Purdue has ...

Eli Lilly had previously announced an expansion of its partnership with Purdue University, with a planned investment of up to $250m over the next eight years to accelerate innovation across the pharma ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.